Role of raloxifene in breast cancer prevention in postmenopausal women: Clinical evidence and potential mechanisms of action

This publication has 44 references indexed in Scilit:

• Hormone replacement therapy regimens and breast cancer risk
  Obstetrics & Gynecology, 2002
• Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells
  Journal of Biological Chemistry, 2002
• Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
  JAMA, 2002
• Department of Error
  The Lancet, 1997
• Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
  The Lancet, 1997
• Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
  Science, 1997
• A realistic clinical perspective of tamoxifen and endometrial carcinogenesis
  European Journal Of Cancer, 1996
• Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually
  JNCI Journal of the National Cancer Institute, 1989
• Glucocorticoids stimulate the growth of mouse mammary carcinoma Shionogi cells in culture
  Molecular and Cellular Endocrinology, 1988
• Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels
  Life Sciences, 1983